Comparison of basilimab and antithymocyte globulin for clinical efficacy in early stage post renal transplantation

OBJECTIVE To compare and analyze clinical efficacy of tow-dose basiliximab and three-dose antithymocyte globulin(ATG) in cadaveric renal transplantation recipients.METHODS59 renal transplant recipients were divided into 2 groups: ATG group(n=42) and basiliximab group(n=17).ATG group received three-dose ATG(100 mg intravenous infusion) on day 0,1,2 after renal transplantation.Basiliximab group received two-dose basiliximab(20 mg intravenous infusion) 2 hours before operation and 4 days after transplantation.The two groups were compared for acute rejection ratio,time of sCr to became normal,graft function(sCr,BUN) following transplantation(1 week,2 weeks,3 weeks,4 weeks after transplantation),infection ratio,urine volume,hospitalization time and total cost.RESULTSThe number of acute rejection episodes were 1 in basiliximab group(5.9%) and 12 in ATG group(28.6%)(P≤0.05).The time of sCr to became normal in basiliximab group is shorter than ATG group(7.4 vs 13.5 days).Graft function of basiliximab group is better than ATG group.Patients in basiliximab group have a lower infection incidence and a shorter hospitalization time than ATG group.CONCLUSIONInterlukin-2 may play a more important role in acute rejection of renal transplantation;Two doses of basiliximab can effectively decreased the incidence of acute rejection in renal allograft recipients.